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Recently a meta-analysis showed an improved survival probability of prophylactic cranial irradiation (PCI) in
limited disease small-cell lung cancer (LD SCLC) in complete remission after chemotherapy.
We evaluated treatment results of PCI+ and PCI7 in these patients. Whether PCI (n¼ 65) or no PCI (n¼ 37) was
administered did not depend either on patients or on tumour characteristics.
After 2 years the incidence of brain metastases was 11% in PCI+ patients and 51% in PCI7 patients. Both
disease-free survival and overall survival were significantly longer after PCI.
PCI reduces the incidence of brain metastases, prolongs brain metastases-free period, and overall survival in LD
SCLC patients in complete remission after chemotherapy.
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Prophylactic cranial irradiation (PCI) was introduced
in 1973 (1). PCI appears to result in an improved survival
probability in limited disease small-cell lung cancer
(LD SCLC) patients who had achieved a complete
remission after chemotherapy (2). In our retrospective
study the effects of PCI on the brain metastases-free period,
disease-free survival and overall survival in LD SCLC
patients with complete remission after chemotherapy have
been analysed.
Methods
The records of 135 SCLC LD patients, treated between
January 1985 and October 1994, were analysed. In nine
patients surgical resection of the primary tumour wasReceived 17 August 2000 and accepted in revised form 5 December
2000.
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apy consisted of five cycles of CDE polychemotherapy:
cyclophosfamide (1?000mgm72) on day 1; doxorubicine
(45mgm72) on day 1, etoposide (100mgm72) on days
1, 3 and 5. All patients underwent re-staging after
full-course chemotherapy, by physical examination, chest
X-ray, bronchoscopy (including biopsies) and computed
tomography of the chest and the brain. A complete
remission (CR) was noted in 102 patients. Thirty-
three patients who did not achieve a CR were excluded
from this study. In 37 patients no PCI was administered
because of individual preference of the physician or the
patient. Between PCI7 patients and PCI+ patients no
difference was found with respect to performance status.
PCI doses ranged from 20 to 42 Gy (median 30 Gy), with
fraction doses of 2, 3 and 5 Gy (median 2?5). Prophylactic
thoracic irradiation (PTI) was administered in 55 PCI+
patients and 12 PCI7 patients after re-staging. Disease-free
survival was determined by the time between initial
diagnosis and first relapse or the end of the follow-up
period. Survival curves were calculated using Kaplan–
Meier analysis. The Cox proportional hazard regression
analysis was used to compare the significance of PCI+
and PCI7.# 2001 HARCOURT PUBLISHERS LTD
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At the time of analysis 77 patients had died, 69 had died
with evidence of progressive SCLC, 19 were alive (13 had
no signs of progressive SCLC), six were lost to follow-up
after a median follow-up period of 18 months (range 12–35
months). The median follow-up period was 17 months
(range 7–117 months). The 2-year overall survival rate was
42% in PCI+ patients and 27% in PCI7 patients.
Recurrent disease was diagnosed in 71% of the PCI+
patients and 92% of the PCI7 patients. Twenty-eight PCI+
patients’ (43%) and 17 PCI7 patients (46%) developed
loco-regional recurrent disease. Seventeen per cent of PCI+
patients developed brain metastases, in contrast to 57% of
PCI7 patients. Within 2 years of follow-up seven PCI+
patients (11%) and 19 PCI7 patients (51%) developed
symptomatic brain metastases. Brain metastases appeared
to be the sole site of recurrence in nine PCI+ patients’
(14%) and 17 PCI7 patients (46%). The median survival
period after the occurrence of symptomatic brain metas-
tases in PCI+ and PCI7 patients was 4?6 and 5?1 months,
respectively. We conclude that PCI+ patients when
compared with PCI7 patients had a prolonged (i) brain
metastases-free period (P50?001; hazard ratio: 7?3; 95%
CI: 3?3–16?4); (ii) disease-free survival (P¼ 0?001; hazard
ratio: 2?4; 95% CI: 1?5–3?8); and (iii) overall survival
(P¼ 0?016; hazard ratio: 1?8, 95%; CI: 1?1–2?9, Fig. 1).
Discussion
We found that PCI prolonged the brain metastases-free
period and survival. Others have reported similar results (3–
5). These results are in line with the results of the meta-
analysis of Auperin et al. (2) concerning 987 LD SCLC
patients who had achieved a complete remission after
polychemotherapy. It has been shown also that PTI leads to
a higher survival rate (6). Our results, therefore, must be
interpreted with some caution since more PCI+ patientsFIG. 1. Overall survival in LD SCLC patients in complete
remission after chemotherapy in PCI+ patients (group 1,
n¼ 65) and PCI7 patients (group 2, n¼ 37), P¼ 0?016.(85%), when compared with PCI7 patients (32%), received
PTI. Loco-regional recurrence rates, however, were similar
both groups. No adverse neurological effects of PCI
were found with moderate fraction doses and low total
doses (7–9). Total dose of PCI should, therefore, not exceed
30 Gy and low fraction sizes (2 Gy) should be given. When
brain metastases became symptomatic survival was very
poor: 4?6 months in PCI+ patients and 5?1 months in PCI7
patients. Both Ryan et al. (10) and Sham et al. (11) reported
similar results.
Based on our observations and recent literature data we
state that PCI should be administered to limited disease
small-cell lung cancer patients in complete remission after
chemotherapy.
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